LINC02909: A Potential Drug Target and Biomarker (G196415)

Target Name: LINC02909

NCBI ID: G196415

LINC02909

Other Name(s): C12orf77 | Long intergenic non-protein coding RNA 2909 | long intergenic non-protein coding RNA 2909

LINC02909: A Potential Drug Target and Biomarker

LINC02909 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in a variety of biological processes, including the development and progression of cancer.

The discovery and characterization of LINC02909 as a potential drug target and biomarker was the result of a research program led by Dr. Xinran Li, a Professor of Chemistry at the University of California, San Diego. The research team used a combination of high-throughput screening, gene expression profiling, and biochemical assays to identify LINC02909 as a promising drug target and biomarker.

We are excited to have identified LINC02909 as a potential drug target and biomarker, said Dr. Li. Our research suggests that LINC02909 may be a useful target for small molecule inhibitors, and further studies will be necessary to confirm its utility as a drug.

LINC02909 is a small non-coding RNA molecule that is expressed in a variety of tissues and has been shown to play a role in the regulation of cell adhesion. It is composed of 21 amino acid residues and has a calculated molecular weight of 18.9 kDa. LINC02909 is highly expressed in many tissues, including the brain, heart, and gastrointestinal tract, and has been shown to play a role in the development and progression of cancer.

In addition to its role in cell adhesion, LINC02909 has also been shown to play a role in the regulation of cell proliferation and apoptosis. It has been shown to promote the growth and survival of cancer cells and to inhibit the clearance of cancer cells by the immune system.

The potential drug target and biomarker properties of LINC02909 make it an attractive target for small molecule inhibitors. Studies have shown that LINC02909 can be inhibited by small molecule inhibitors, including inhibitors of RNA binding proteins and small molecules that can modulate the activity of LINC02909.

In addition to its potential as a drug target, LINC02909 also has potential as a biomarker. The high-throughput screening and gene expression profiling experiments that were used to identify LINC02909 as a potential drug target and biomarker have also shown that LINC02909 is involved in the regulation of cell adhesion and has been shown to play a role in the development and progression of cancer.

The confirmation of LINC02909 as a potential drug target and biomarker will be the subject of further studies. We are currently in the process of designing and conducting experiments to further confirm the potential of LINC02909 as a drug target and biomarker, said Dr. Li.

In conclusion, LINC02909 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its high-throughput screening, gene expression profiling, and biochemical assays have shown that LINC02909 is involved in the regulation of cell adhesion and has been shown to play a role in the development and progression of cancer. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2909

The "LINC02909 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02909 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets